Secondaries announced 10.17.2016
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Nektar Therapeutics Symbol: NKTR Price: Last trade $15.67 Trade Date: 10/19 Shares: 11.2 million Underwriter(s)J.P. Morgan Rating=Subscription Needed